Medicinal-cannabis research in New Zealand

New Zealand’s medicinal-cannabis research landscape sits inside a tightly regulated pharmaceutical framework. The Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (MCA) within Medsafe, has been fully operational since 1 April 2020 under the Misuse of Drugs Act. The scheme legalises access via a prescription from a medical practitioner, and preparations must meet GMP standards and be approved by the Ministry of Health. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated items; the legal form is a manufactured pharmaceutical, and the raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.

What counts as medicinal cannabis in New Zealand

Under the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, medicinal cannabis is a prescription medicine. The Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (MCA) within Medsafe, sets the legal framework. Preparations must be manufactured to GMP standards, contain specified amounts of THC or CBD, and be approved by the Ministry of Health before they can be prescribed. The scheme does not legalise raw plant material for general use. The raw flower is available only through a prescription and dispensed by a pharmacy. This is the single most important legal boundary to understand.

Key legal and regulatory points

The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and came into force on 1 April 2020.
The Medicinal Cannabis Agency (MCA), part of Medsafe, issues licences for cultivation, manufacture and supply.
Preparations must meet GMP (Good Manufacturing Practice) standards and be approved by the Ministry of Health before they can be prescribed.
Prescribing is restricted to medical practitioners. Items are dispensed through a pharmacy, not a dispensary or retail outlet.
Cannabis remains a controlled drug under the Misuse of Drugs Act 1975; the scheme provides a legal pathway for prescription preparations.
Raw flower is available only as a prescribed pharmaceutical dispensed through a pharmacy. It is typically vaporised, not smoked.
Medsafe and the MCA oversee approval, licensing and quality standards.
The NZ Formulary lists cannabis preparations and provides prescribing guidance for clinicians.
Healthify (previously Health Navigator) provides patient-facing information on medicinal cannabis.

The patient pathway

Consult a doctor.
The doctor assesses eligibility and obtains informed consent.
The doctor writes a prescription for a specific preparation.
A pharmacy sources a Medsafe-approved preparation.
The pharmacist dispenses and counsels.
The patient pays the full cost (no subsidy).
Follow-up is scheduled.

The scheme does not allow smoking raw plant material. Legal forms include dried flower for vaporisation, oils, capsules and oral sprays.

What counts as research in New Zealand

Distinguish clinical research (trials, observational studies) from regulatory approval (Medsafe assessment) and real-world evidence (prescriber and patient-reported outcomes). Most “research” a patient sees is not a clinical trial but a registration or a retrospective audit. Use the NZ Formulary as the reference standard for prescribing decisions.

Where the evidence sits today

Systematic reviews show modest support for chronic pain, some support for nausea and vomiting in chemotherapy, and limited support for epilepsy. Most studies are short-term and industry-funded. New Zealand-specific clinical trials are scarce, but the Ministry of Health funds and reviews research.

The strongest backing is for chronic pain in adults (moderate quality), spasticity in multiple sclerosis (moderate) and nausea from chemotherapy (moderate). The weakest is for anxiety, depression and sleep disorders, where the data are mixed or low quality.

Who is doing the research

The University of Auckland (Centre for Addiction Research), the University of Otago (Christchurch), the Medical Cannabis Research Collaborative (MCRC), a New Zealand group, and the Health Research Council of New Zealand (HRC) fund and conduct studies. Medsafe’s Medicinal Cannabis Agency regulates the scheme. The Ministry of Health publishes the Medicinal Cannabis Scheme guidance. Clinical trials are registered with the Australian New Zealand Clinical Trials Registry (ANZCTR).

Cannabinoids and preparations

The NZ Formulary includes cannabis monographs, but clinicians are not restricted to them. As of 2025 the formulary lists preparations, yet the evidence base remains limited. Most prescribers rely on international systematic reviews. The NZ Formulary and Healthify are the official patient and prescriber resources for medicinal cannabis in New Zealand.

Safety and daily life

Before you drive or operate machinery, confirm with your prescriber whether your preparation impairs you. THC-containing items can cause sedation, dizziness and cognitive slowing. Do not drive until you know how a dose affects you, and never combine medicinal cannabis with alcohol or other sedatives. Report any adverse effects to your doctor and to the Centre for Adverse Reactions Monitoring (CARM).

Costs and access

No government subsidy exists. You pay the full cost of the consultation, the preparation and the pharmacy dispensing fee. Prices vary by formulation and dose. Ask the pharmacy for a quote before filling a new prescription, and check whether your GP charges extra for the consultation.

Checklist for patients and prescribers

Confirm the preparation is Medsafe-approved and listed in the NZ Formulary or supplied under a verified exemption.
Ask what the evidence actually shows for your condition: is it moderate, limited or absent?
Check whether the claim comes from a registered clinical trial (ANZCTR) or from a product registration.
Verify the prescriber is a registered medical practitioner.
Confirm the pharmacy is licensed and the item meets GMP standards.
Do not buy unregulated items online or from a dispensary-style outlet.
Report adverse effects to CARN.

Where to go from here

Start with the NZ Formulary and Healthify. If you are a prescriber, consult the Medicinal Cannabis Agency’s guidance on Medsafe’s website. If you are a patient, book a consultation with a GP who is familiar with the scheme and ask for a copy of the informed-consent form before you agree to a prescription.